The alpha/beta hydrolase superfamily is comprised of diverse members that are involved in important biochemical processes and related to various diseases.
They have unrelated sequences, various substrates, and different kinds of catalytic activities, yet they share the same canonical alpha/beta hydrolase fold, which consists of an eight-stranded parallel alpha/beta structure.
They are also characterized by a catalytic triad composed of a histidine, an acid and a nucleophile.
Members of this superfamily are often drug targets for treating diseases, such as diabetes, Alzheimer’s disease, obesity and blood clotting disorders.
ABHD1 plays a role in metabolizing smoking xenobiotics.
ABHD2 participates in the development of atherosclerosis.
ABHD4 is involved in an alternative synthesis pathway of NAE.
ABHD4 is a lysophospholipase selective for N-acyl phosphatidylethanolamine (NAPE) which participates in the biosynthesis of N-acyl ethanolamines.
Mutations in ABHD5 contribute to Chanarin-Dorfman syndrome.
ABDH6 may play a role in nervous system metabolism and signaling.
ABHD14A is possibly involved in granule neuron development.
Applications:Suitable for use in Western Blot and Immunohistochemistry.
Other applications not tested.
Recommended Dilution:Western Blot: 1:500-1:1000Immunohistochemistry: 1:50-1:200Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by immunoaffinity chromatography.
Form：Supplied as a liquid in PBS, pH 7.3, 0.05% sodium azide.
Specificity：Recognizes human ABHD4. Species Crossreactivity: mouse and rat
Isotype：IgG
Calc Applications Abbrev：IHC WB
Calc Crossreactivity：Hu Mo Rt
Immunogen：Synthetic peptide corresponding to human ABHD4.
